Attovia Therapeutics, Inc.
ATTO
IPO
$22.86
-$0.80-3.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | 450.00K | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | 450.00K | -- | -- | ||
| Cost of Revenue | 18.71M | 16.51M | 13.40M | ||
| Gross Profit | -18.26M | -16.51M | -13.40M | ||
| SG&A Expenses | 3.31M | 3.21M | 3.03M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 22.25M | 19.96M | 16.62M | ||
| Operating Income | -21.80M | -19.96M | -16.62M | ||
| Income Before Tax | -20.69M | -18.66M | -14.44M | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -20.69M | -18.66M | -14.44M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -20.69M | -18.66M | -14.44M | ||
| EBIT | -21.80M | -19.96M | -16.62M | ||
| EBITDA | -21.56M | -19.71M | -16.41M | ||
| EPS Basic | -4.88 | -4.49 | -3.71 | ||
| Normalized Basic EPS | -3.05 | -2.81 | -2.32 | ||
| EPS Diluted | -4.88 | -4.49 | -3.71 | ||
| Normalized Diluted EPS | -3.05 | -2.81 | -2.32 | ||
| Average Basic Shares Outstanding | 4.24M | 4.15M | 3.90M | ||
| Average Diluted Shares Outstanding | 4.24M | 4.15M | 3.90M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||